The Twelfth Amendment to the PREP Act Declaration, issued in December 2024, extended liability immunity for COVID-19 vaccine manufacturers through December 31, 2029 — another five years of legal protection for an industry that has generated hundreds of billions in revenue.
The Countermeasures Injury Compensation Program (CICP) remains the only avenue for those injured by COVID vaccines, and its track record is abysmal: approximately 10% of claims receive any compensation, compared to 40% through the standard Vaccine Injury Compensation Program (VICP).
“CICP compensation is limited to reasonable medical expenses, lost employment income, and death benefits. It does not cover pain and suffering, legal fees, or offer the right to appeal.”
The key difference between CICP and VICP: VICP operates through a court process with established injury tables, the right to counsel, and judicial review. CICP is an administrative process with no appeal, no injury table, a higher burden of proof, and a one-year filing deadline.
The extension means vaccine injuries will not transition to the more favorable VICP system until at least 2030 — leaving injured individuals with a compensation system designed to deny their claims.
